Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?

To: DoubleOddBuck who wrote (32269)	1/13/1999 12:19:00 PM
From: pitchlyn	Respond to of 34592

PRLN has some interesting Anti-cancer News just released: Wednesday January 13, 10:25 am Eastern Time Company Press Release SOURCE: Paracelsian Inc. Paracelsian Announces Confirmation of Anti-Cancer Effects of Herbal Extracts ITHACA, N.Y., Jan. 13 /PRNewswire/ -- Paracelsian Inc. (OTC Bulletin Board: PRLN - news) announced today the completion of testing of four potential anti-cancer drug agents in cell culture systems at Roswell Park Cancer Institute in Buffalo, New York. All four samples, including the compound Andrographolide for which Paracelsian has a U.S. Patent Pending, demonstrated significant anti-cancer activity against a human breast cancer cell line. The samples were selected from Paracelsian's extensive library of nearly 2,800 Traditional Chinese Medicines The three most active samples are currently being tested at the Southern Research Institute for in vivo (live) anti-tumor activity against human breast cancer and prostate cancer tumors implanted in mice. Results of this testing are expected in the Spring. Further testing of all four samples, focusing on inhibiting tumor growth and angiogenesis, is planned at Roswell Park in the immediate future. ''This study conducted at Roswell Park represents important validation of our internal testing of these four samples,'' said Bernie Landes, the Company's President and CEO. ''The level of anti-cancer activity demonstrated by three of the samples was especially intriguing,'' continued Mr. Landes. ''We are very excited with these results. We look forward to continued testing of these samples and others from our extensive library at the Southern Research Institute and Roswell Park as part of a more aggressive program of drug discovery and development,'' added Mr. Landes.